International Journal of Hematology and Oncology 2020, Vol 30, Num 2 Page(s): 130-137
Cytarabine Induction Followed by Imatinib Post-Induction Therapy in Patients with Acute Myeloid Leukaemia - Limited Effects in a Case Series

Patrick BRUECK1, Oliver G. OTTMANN2, Elizabeth RAMOS-LOPEZ3, Dieter HOELZER4, Angelika BOEHME4, Mathias RUMMEL1

1University of Giessen, Medical Clinic for Hematology and Medical Oncology, Giessen, GERMANY
2University of Frankfurt, Department of Medicine, Hematology and Oncology, University of Frankfurt, GERMANY
3University of Frankfurt, Department of Medicine, Endocrinology and Diabetes, GERMANY
4Oncologikum, Frankfurt a. M., GERMANY

Keywords: Imatinib mesylate, Acute myeloid leukaemia, Post-induction therapy, Elderly patient
Elderly patients with acute myeloid leukaemia frequently cannot undergo intensive chemotherapy due to comorbidities. We report a
retrospective case series of elderly patients with AML treated with low dose cytarabine induction. Eleven patients with at least 25%
of bone marrow blasts expressing c-kit received Imatinib post-induction therapy, 7 patients entered as controls. Haematologic responses
were only slightly better in the Imatinib cohort. No correlation of the response to Imatinib with c-kit expression was noted.
Partly due to two early deaths in the control cohort, survival was longer in the Imatinib cohort. Imatinib post-induction therapy after
cytarabine induction is feasible in elderly patients with AML not eligible for standard induction but responders to Imatinib have only
limited benefit from this low-toxic therapy while no predictive response markers could be found.